P Paliard

ORCID: 0000-0002-0826-7573
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Liver Diseases and Immunity
  • Drug-Induced Hepatotoxicity and Protection
  • Pediatric Hepatobiliary Diseases and Treatments
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Organ Transplantation Techniques and Outcomes
  • Hepatitis B Virus Studies
  • Esophageal and GI Pathology
  • Gallbladder and Bile Duct Disorders
  • Amoebic Infections and Treatments
  • Vascular Anomalies and Treatments
  • Gastrointestinal disorders and treatments
  • Metabolism and Genetic Disorders
  • Alcohol Consumption and Health Effects
  • Eosinophilic Esophagitis
  • Pharmacological Effects and Toxicity Studies
  • Hepatitis C virus research
  • Tracheal and airway disorders
  • Abdominal Trauma and Injuries
  • Genetic and Kidney Cyst Diseases
  • Toxoplasma gondii Research Studies
  • Inflammatory Bowel Disease
  • Parasitic Infections and Diagnostics
  • Drug Transport and Resistance Mechanisms

Hôpital Edouard Herriot
1997-2022

Université Claude Bernard Lyon 1
2018-2022

Hospices Civils de Lyon
2001-2022

Hôpital Lyon Sud
1999

Inserm
1978-1999

Fondation Mérieux
1999

Institut Pasteur
1978-1979

Hôpital de la Croix-Rousse
1978

<h3>Background</h3> Alcohol relapse can negatively influence the outcome after liver transplantation (LT). The aim of our study was to identify factors that could be associated with recurrence harmful alcohol consumption LT. <h3>Methods</h3> A total 387 consecutive patients (23.8% women) who underwent LT for alcoholic cirrhosis in Geneva, Switzerland, and Lyon, France, between 1989 2005 were evaluated. Mean ± SD age 51.3 7.5 years. Follow-up time 61.2 47.5 months. potential it studied....

10.1001/archinte.167.11.1183 article EN Archives of Internal Medicine 2007-06-11

Alcoholic liver disease is a leading indication for transplantation (LT). The aim of this study was to evaluate long-term results and survival prognostic factors LT in from large cohort patients.From October 1990 2005, 305 consecutive patients with alcoholic cirrhosis (from 594 presenting cirrhosis, i.e., 51.3%) underwent our center. There were 229 men 76 women, median age 50 yr (range 30-68). Clinical biological variables possible value analyzed.Global rate 92.6% at 1 yr, 88.5% 3 84.3% 5...

10.1111/j.1572-0241.2007.01079.x article EN The American Journal of Gastroenterology 2007-02-21

Interferon alpha (IFN) is the corner stone drug for treatment of recurrent hepatitis C (HCV) in liver transplant (LT) recipients. One its serious potential adverse effects acute and chronic rejection. The aim this study was to review our experience using IFN-based therapy, order examine incidence risk factors rejection, outcome patients who developed Between September 1990 December 2004, 70 LT recipients were treated. Patients started antiviral 16 (1-137) months after LT. Histological...

10.1111/j.1600-6143.2006.01590.x article EN cc-by-nc-nd American Journal of Transplantation 2006-11-07

5 patients treated with perhexiline maleate, 200–400 mg/day for at least 6 months, exhibited evidence of hepatitis. The picture was very similar to acute alcoholic hepatitis, clinically, biologically and histologically presence necrosis, Mallory's hyaline, polynuclear infiltration a lesser degree, steatosis. Association peripheral neuropathy, hypoglycemia, renal failure appears strikingly frequently. evolution severe since 3 died within even after treatment withdrawal. Further studies are be...

10.1159/000198145 article EN Digestion 1978-01-01

While hemorrhagic complications of portal cavernoma are frequent, compression the bile ducts by is uncommon and treatment still a matter for debate. We report here six new cases in order to describe: (a) clinical, biological, morphological features this condition, (b) long-term results combined endoscopic surgical treatment. The median age patients at time diagnosis was 36.5 years. circumstances were acute cholangitis (n=3), asymptomatic biological cholestasis (n=1), pruritus, jaundice...

10.1055/s-2003-38779 article EN Endoscopy 2003-04-17

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide long-term evaluation of graft status after LT for HHT, focus on the risk recurrence. The present study included all patients prospectively followed up HHT Lyon Transplant Unit from 1993 to 2010, survival more than 1 year. Protocol clinical, radiological, and histological examinations were performed at regular intervals. Fourteen (13...

10.1002/hep.30424 article EN Hepatology 2018-12-14

Idiopathic portal hypertension is a rare clinical syndrome which may be associated with spectrum of histological lesions, including nodular regenerative hyperplasia and incomplete septal cirrhosis. Here, we report eight adult patients idiopathic who experienced an unusually severe evolution characterized by the development progressive hepatic failure requiring orthotopic liver transplantation. Our aims are: (a) to stress distinctive presentation these patients, (b) describe their biological...

10.1080/003655201300051298 article EN Scandinavian Journal of Gastroenterology 2001-04-01

BACKGROUND/AIMS Nodular regenerative hyperplasia of the liver is a histological lesion usually associated with systemic diseases, haematological malignancies, or drugs. Its prognosis depends on portal hypertension, which well tolerated and requires medical management only. PATIENTS Three unrelated families, in two sibling adult male patients presented nodular liver, were studied. METHODS Complete clinical charts biopsy specimens available for all patients. In addition, explanted livers...

10.1136/gut.45.2.289 article EN Gut 1999-08-01

The most dramatic complication of portal hypertension in cirrhotic patients is oesophageal variceal bleeding. Moreover, with bleeding unresponsive to medical and endoscopic treatment have a poor prognosis.The aim this study was evaluate the efficacy early transjugular intra-hepatic portosystemic shunt (TIPS) refractory bleeding.TIPS performed for 28 (17 were stage Child C), successfully 26. Variceal controlled all but one stented patient.There no mortality associated procedure. two failure...

10.1097/00042737-200104000-00011 article EN European Journal of Gastroenterology & Hepatology 2001-04-01

Vinyl chloride (VC), an industrial toxic gas, has a dose-dependent carcinogenicity in rodents and been responsible for multiple cases of liver angiosarcoma humans. The aim this study was to describe histopathologic alterations evaluate risk factors hepatocellular carcinoma two workers from the same plant, both whom had primary nonangiosarcoma tumors were exposed VC.Clinical, biochemical, serologic, pathologic data reviewed at time hepatic resection. Clinical biologic follow-up available...

10.1002/(sici)1097-0142(19970501)79:9<1671::aid-cncr6>3.0.co;2-f article EN Cancer 1997-05-01

5 human cases of hepatoma have been chosen with respect to their different seric alpha-fetoprotein (alpha-FP) level and histological characters. Cells producing alpha-FP studied specific horseradish-peroxidase-labelled immunoglobulins. Ultrastructural examination shows that is present in the cytoplasm some tumoral hepatocytes. also rare nontumoral hepatocytes a nonsecreting hepatoma. differences are described according grade differentiation cell population. production appears be restricted...

10.1159/000198222 article EN Digestion 1978-01-01

Background. In this pilot study, we present the results of treatment early (3 months after liver transplantation) acute rejection episodes by increasing only tacrolimus doses. Methods. Ten patients who received as primary experienced mild (one case), moderate (four cases), or severe (five cases) episodes. Tacrolimus dosing was increased 1-2 mg every 1 2 days until hepatic enzymes started to improve. Steroid basic daily doses were kept unchanged. Results. With dose a median 1.89-fold (range:...

10.1097/00007890-199811150-00012 article EN Transplantation 1998-11-01
Coming Soon ...